Lilly Updates On Cymbalta, Zyprexa, Cialis Expected At Dec. 9 Meeting
This article was originally published in The Pink Sheet Daily
Cymbalta was launched for depression in August; Lilly anticipates first half 2005 approval of duloxetine for stress urinary incontinence under the Yentreve name. Patent challenges to the antipsychotic Zyprexa and Lilly’s cost-cutting efforts are also likely topics at the investor meeting.
You may also be interested in...
Indianapolis court plans special procedures for announcing its bench verdict on infringement and invalidity claims involving Zyprexa. Lilly and ANDA filers Ivax, Dr. Reddy’s and Teva are admonished “not to speculate about the timing of the opinion.”
FDA’s neuropharm and urology review divisions hold differing opinions on duloxetine drug interactions, Cymbalta review documents indicate. Due to potential QT risk, urology division delays Yentreve approval for stress urinary incontinence; neuropharm division believes potential QT effect can be considered post-approval.
The restructuring program will affect R&D, manufacturing and sales & marketing. The program is expected to be completed by Mach 31, 2005, and will result in net savings of $150 mil. for 2005. Lilly’s third quarter sales rose 4% to $3.28 bil.